Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) traded up 71.4% on Tuesday . The company traded as high as C$0.12 and last traded at C$0.12. 592,088 shares changed hands during trading, an increase of 516% from the average session volume of 96,162 shares. The stock had previously closed at C$0.07.
Hemostemix Stock Performance
The firm has a fifty day simple moving average of C$0.08 and a 200-day simple moving average of C$0.07. The firm has a market cap of C$9.58 million, a price-to-earnings ratio of -5.50 and a beta of 0.20.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Further Reading
- Five stocks we like better than Hemostemix
- How to Capture the Benefits of Dividend Increases
- 3 Legacy Tech Companies Reemerging as AI Leaders
- Overbought Stocks Explained: Should You Trade Them?
- Analysts’ Favorite Cybersecurity Stocks: 3 Top Picks
- The 3 Best Blue-Chip Stocks to Buy Now
- Analysts Are Bullish: 3 Tech Giants With Upgraded Price Targets
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
